Welcome to OncologyPRO, the home of Esmo’s educational and scientific resources.

Men carrying germline pathogenic variants of MSH2 or MSH6 have an increased risk of prostate cancer and may benefit from targeted prostate-specific antigen screening

Adding liposomal irinotecan to fluorouracil and leucovorin may improve the outcome of patients previously treated for metastatic biliary tract cancer

Somatic oncogenic variants and pancytopenia may signal an increased risk of PARP inhibitor-related myeloid neoplasms

Individuals carrying a single nucleotide polymorphism in KCNAB1 may have an increased risk of developing hypertension during bevacizumab therapy

Chemorefractory or relapsed gestational trophoblastic neoplasia may respond to camrelizumab and apatinib treatment

Older patients undergoing cancer treatment are less likely to experience grade 3 or more severe chemotherapy toxicity if given a multidisciplinary assessment during treatment planning

Health-related quality of life and symptom scores are maintained in patients with clear cell renal cell carcinoma taking adjuvant pembrolizumab

 REGISTRI Results Reported For First-line Regorafenib In KIT/PDGFR Wild-Type Metastatic GIST